Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catalina Raymond

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Journal of Neuro-Oncology|June 3, 2025
Super-resolution sodium MRI of human gliomas at 3T using physics-based generative artificial intelligenceCatalina Raymond, Jingwen Yao, Alfredo L Lopez Kolkovsky, et al.
Journal of Neuro-Oncology|April 14, 2025
Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF responseFrancesco Sanvito, Irina Kryukov, Jingwen Yao, et al.
Neuro-Oncology|December 5, 2021
Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitorsAkifumi Hagiwara, Talia C Oughourlian, Nicholas S Cho, et al.
Neuro-Oncology Advances|August 11, 2021
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastomaBenjamin M Ellingson, Kunal Patel, Chencai Wang, et al.
CNS Oncology|November 13, 2024
Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastomaSonoko Oshima, Jingwen Yao, Samuel Bobholz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2023
Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent GlioblastomaBenjamin M Ellingson, Akifumi Hagiwara, Connor J Morris, et al.
AJNR. American Journal of Neuroradiology|May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
NMR in Biomedicine|June 15, 2022
Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumorsNicholas S Cho, Akifumi Hagiwara, Jingwen Yao, et al.
Neuroimage. Clinical|December 16, 2021
"Aerobic glycolytic imaging" of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imagingAkifumi Hagiwara, Jingwen Yao, Catalina Raymond, et al.
Journal of Neuro-Oncology|June 9, 2023
Multi-nuclear sodium, diffusion, and perfusion MRI in human gliomasNicholas S Cho, Francesco Sanvito, Shruti Thakuria, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Journal of Neuro-Oncology|June 3, 2025
Super-resolution sodium MRI of human gliomas at 3T using physics-based generative artificial intelligenceCatalina Raymond, Jingwen Yao, Alfredo L Lopez Kolkovsky, et al.
Journal of Neuro-Oncology|April 14, 2025
Advanced imaging characterization of post-chemoradiation glioblastoma stratified by diffusion MRI phenotypes known to predict favorable anti-VEGF responseFrancesco Sanvito, Irina Kryukov, Jingwen Yao, et al.
Neuro-Oncology|December 5, 2021
Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitorsAkifumi Hagiwara, Talia C Oughourlian, Nicholas S Cho, et al.
Neuro-Oncology Advances|August 11, 2021
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastomaBenjamin M Ellingson, Kunal Patel, Chencai Wang, et al.
CNS Oncology|November 13, 2024
Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastomaSonoko Oshima, Jingwen Yao, Samuel Bobholz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2023
Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent GlioblastomaBenjamin M Ellingson, Akifumi Hagiwara, Connor J Morris, et al.
AJNR. American Journal of Neuroradiology|May 30, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)Benjamin M Ellingson, Timothy F Cloughesy, Xiaobu Ye, et al.
NMR in Biomedicine|June 15, 2022
Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumorsNicholas S Cho, Akifumi Hagiwara, Jingwen Yao, et al.
Neuroimage. Clinical|December 16, 2021
"Aerobic glycolytic imaging" of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imagingAkifumi Hagiwara, Jingwen Yao, Catalina Raymond, et al.
Journal of Neuro-Oncology|June 9, 2023
Multi-nuclear sodium, diffusion, and perfusion MRI in human gliomasNicholas S Cho, Francesco Sanvito, Shruti Thakuria, et al.
Pageof 7